InveniAI and Kyowa Kirin Enter AI-Powered Novel Target Discovery Collaboration

Expansion of existing collaboration will leverage InveniAI technology to identify, evaluate, and optimize novel targets for Kyowa Kirin’s antibody technology

Kyowa Kirin will select multiple programs to advance into clinical development

InveniAI is eligible to receive an upfront payment, development and commercial milestones, and royalties

InveniAI, a global leader in pioneering the application of artificial intelligence (AI) and machine learning (ML) to transform innovation across drug discovery and development, and Kyowa Kirin Co., Ltd., a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, are pleased to announce they have expanded their collaboration agreement to harness the power of InveniAI’s AI-platform, AlphaMeld, for novel target discovery.

Recommended AI News: Recruiter.com to Acquire OneWire, a Leading Financial Services Hiring Platform

InveniAI and Kyowa Kirin have been collaborating since 2018, to maximize Kyowa Kirin’s portfolio value through the re-innovation of an existing therapeutic pipeline into new disease indications utilizing AlphaMeld. Through this expansion, Kyowa Kirin will leverage AlphaMeld for novel target discovery and validation to generate a clinical pipeline of therapeutic antibodies that address the enduring unmet needs of patients across multiple diseases. Under the terms of the agreement, Kyowa Kirin will select multiple programs to advance into clinical development.

Recommended AI News: SomaLogic Adds $81 Million to Series A Financing Totaling $214 Million

“As we work towards our mission to contribute to human health and well-being worldwide through state-of-the-art therapeutic modalities, we are excited to advance the next generation of antibody technology which offers numerous advantages over traditional monoclonal antibodies,” said Yoshifumi Torii, Ph.D., Executive Officer, Vice President, Head of R&D Division of Kyowa Kirin. “We are thrilled to partner with InveniAI to leverage artificial intelligence and machine learning to comprehensively identify viable connections between novel targets and diseases at unprecedented scale and speed. The expansion of the agreement will allow us to prioritize and advance our programs into clinical development with the highest probability of success while minimizing time and cost.”

Recommended AI News: Verizon Business Launches On Site LTE, a Private Network for Enterprise Customers